Search Results 311-320 of 17433 for Interferon
Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks prior to enrollment. Known brain metastases, unless these metastases ...
CMV -specific immune reconstitution after solid organ and allogeneic hematopoietic stem cell transplant. Evaluation of letermovir and maribavir to manage ...
Interferon Beta-1a; Methadone; Nelfinavir; Probenecid; Rifabutin; Rifapentine; Tipranavir. Other Interactions. Certain medicines should not be used at or around ...
... interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004 Jan 27; 77 (2):190-4. View PubMed; Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz ...
Encorafenib is also used in combination with binimetinib to treat non-small cell lung cancer (NSCLC) that has spread in patients who have BRAF V600E mutations.
Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents and immunomodulating agents (eg, interleukins, interferons, ...
This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin ...
Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 4 weeks or 5 half-lives of the drug, whichever is ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.